Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 PK study of novel PTH formulations EB612 for the treatment of hypoparathyroidism

Next Previous
Trial Profile

A phase 1 PK study of novel PTH formulations EB612 for the treatment of hypoparathyroidism

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Entera Bio

Most Recent Events

  • 09 Aug 2024 According to an Entera Bio media release, Research and development expenses for the three months ended June 30, 2024 were $1.1 million, as compared to $1.2 million for the three months ended June 30, 2023. The decrease of $0.1 million was primarily due to a decrease of $0.3 million in clinical expenses for our Phase 1 PK study related to our new generation platform and new formulations for EB612, which completed its first stage in 2023.
  • 09 Aug 2024 According to an Entera Bio media release, Entera showed that the data presented at ENDO 2024 supports potentially moving the BID (twice-daily) tablet dose to Phase 2 development in patients with hypoparathyroidism.
  • 09 Aug 2024 According to an Entera Bio media release, In June 2024, Entera presented Phase 1 clinical data for its hypoparathyroidism focused investigational program, EB612, at the Endocrine Society ENDO 2024 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top